Neurons rely extensively on post-transcriptional mechanisms to control the location and amounts of specific proteins 1 . A post-transcriptional mechanism that recently has been found to have major roles in neurons is nonsense-mediated RNA decay (NMD), an RNA turnover pathway that is conserved from yeast to man [2] [3] [4] . NMD was originally discovered as an RNA surveillance mechanism that degrades aberrant RNAs harbouring premature translation termination codons (PTCs) 5 . This quality control function of NMD has medical implications, as the truncated proteins translated from PTC-bearing mRNAs can sometimes act as dominant-negative proteins that cause disease. Indeed, there is considerable evidence that NMD reduces genetic disease symptoms by decreasing the levels of such potentially deleterious proteins 3, 6, 7 .
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NMD degrades subsets of normal mRNAs
In recent years, it has become clear that NMD is more than merely an RNA surveillance pathway to protect cells from transcripts that contain genetic mutations. Genome-wide studies -first conducted in yeast and later in higher eukaryotes -have demonstrated that a wide variety of normal mRNAs are subject to rapid decay by NMD 4, [8] [9] [10] [11] . These studies showed that knockout or depletion of NMD factors causes a substantial subset (~5-10%) of normal mRNAs to be upregulated. Although it has remained unclear what proportion of these upregulated mRNAs are directly targeted by NMD, a wealth of studies have identified likely NMD target transcripts using a battery of different approaches, including RNA half-life analysis and immunoprecipitation analysis of mRNAs bound by the NMD factor, up-frameshift protein 1 (UPF1) (Refs 4, 10, 12, 13 ).
Why does NMD degrade subsets of normal mRNAs?
As we argue below, there is increasing evidence that NMD serves as a regulatory mechanism to control the steady-state levels of such mRNAs in different biological contexts. This observation follows from the fact that NMD itself is a highly regulated pathway 14, 15 . Thus, rather than being simply 'on' or 'off ' , NMD efficiency can be regulated, resulting in differential degradation of NMD targets. For example, decreased NMD efficiency at a specific developmental stage leads to stabilization of NMD target RNAs at that developmental stage. Conversely, increased NMD magnitude will destabilize NMD target RNAs. Such shift in the levels of NMD target RNAs has the potential to drive and shape biological processes; indeed, NMD has been shown to influence many biological processes, including differentiation, cell survival and stress responses 4, [16] [17] [18] [19] [20] . (fiG. 1) . Some of these factors are involved in the 'recognition phase' of NMD, which establishes which transcripts are NMD targets. This recognition phase requires several NMD factors, including UPF1, UPF2 and UPF3B. The 'decay phase' of NMD is driven by other factors, including suppressor with morphological effect on genitalia-6 (SMG6), an endonuclease that cleaves NMD target mRNAs near the stop codon terminating the main open reading frame (ORF) 4 . NMD is triggered by so-called 'NMD-inducing features' , all of which revolve around translation termination. In most transcripts, the stop codon terminating the main ORF is in the last exon, a context that typically does not trigger NMD. By contrast, transcripts harbouring the stop codon in a middle exon are targeted for decay by NMD by virtue of the exon-exon junctions downstream of the stop codon (for the reasons described below; see fiGs. 1,2a,b) . Although originally considered to be rare 21 , mRNAs with middle-exon stop codons have since been shown to be fairly common, probably for regulatory purposes, as described below.
NMD factors and NMD-inducing features NMD is a complex pathway involving numerous factors
In some cases, transcripts with a middle-exon stop codon are generated by alternative RNA splicing. For example, this may involve inclusion of an alternative middle exon that includes an in-frame stop codon, sometimes called a 'poison exon' . As a result, this transcript becomes an NMD target (fiGs. 2,3). Alternative splice donors or acceptors that lead to a shift in the reading frame or inclusion of a sequence with an in-frame stop codon also lead to a transcript that is targeted by NMD (fiG. 3) . Thus, alternative splicing can suppress the 'functional output' of a gene by causing its encoded transcripts to be rapidly degraded.
Exon-exon junctions downstream of stop codons elicit NMD by acting as nucleation points that recruit a set of NMD-promoting proteins collectively called the exon junction complex (EJC) 22, 23 . In a current consensus model, RNA decay is triggered in an EJC-dependent manner through a series of steps. First, when the ribosome reaches a stop codon defining the end of the main ORF, this leads to the formation of a termination complex (fiG. 1) . The stop codon is recognized by eukaryotic release factors (eRFs), which are proteins that physically connect the termination complex to the EJC and thereby trigger NMD. A key protein in this coupling event is UPF3B, which binds both the EJC and eRFs, thereby acting as a bridge that forms an NMD-promoting complex 24, 25 . Also present in this NMD-promoting complex are the RNA helicase UPF1 and the adaptor protein UPF2 (Ref. 25 ), the latter of which may also directly interact with eRFs 26 (fiG. 3) . The formation of this NMD-promoting complex enables UPF1 to be phosphorylated by SMG1, leading to the recruitment of proteins critical for the effector phase of NMD 27 . Notably, the formation of the complex comprising the stop-codon-bound ribosome and the EJC is limited to EJCs downstream of the main ORF stop codon, as upstream EJCs are ejected during the pioneer round of translation 28 . As a consequence, only stop codons in middle exons, not the final exon, elicit EJC-dependent NMD. This limitation provides a simple mechanism by which PTCs are distinguished from normal stop codons.
NMD is typically triggered only by stop codons at least ~50 nt upstream of the last exon-exon junction 21 . This '−50 boundary rule' most likely derives from the ability of the ribosome to displace the EJC from an mRNA [28] [29] [30] . Stop codons closer than ~50 nt to the final exon-exon junction would be expected to elicit ribosome-mediated displacement of the most 3′ EJC before translation termination, as the EJC is typically centred ~24 nt upstream of the exon-exon junction 23 and the ribosome footprint is ~20 nt on either side. Without at least one retained EJC, NMD is not elicited.
In addition to downstream exon-exon junctions, other NMD-inducing features have been identified, including long 3′ untranslated regions (UTRs) and short upstream ORFs 4 ( fiG. 2c,d ).
NMD and neural disease UPF3B and intellectual disability. In 2007, Gecz and colleagues 31 reported that mutations in the X-linked NMD gene UPF3B cause intellectual disability (ID) in humans (TAble 1) . Through sequence analysis of X chromosome genes from 250 families with X-linked ID, they identified UPF3B mutations in 4 families. Later pedigree studies identified several other families with UPF3B mutations; in each case, males with such mutations had ID [32] [33] [34] [35] . Intriguingly, several of these ID individuals also have schizophrenia (SCZ) or autism spectrum disorder (ASD), raising the possibility that NMD dysfunction also contributes to these neurodevelopmental disorders.
As one approach to understand the underlying mechanism, Upf3b-null mice have been generated 36 . These NMD-deficient mice are viable and are not significantly different from wild-type controls in most respects. However, they exhibit a profound defect in pre-pulse inhibition (PPI), a measure of sensorimotor gating commonly deficient in individuals with SCZ and other brain disorders. They also have cued and contextual fear learning deficits, but no significant defect in spatial memory tests (Y maze and Barnes maze). This selective learning defect is intriguing and suggests a role for UPF3B in the generation and/or function of neural circuits specifically important for fear-conditioned learning. Consistent with A key interaction is between the RNA-binding protein up-frameshift protein 3B (UPF3B) and the exon junction complex (EJC), the latter of which is composed of the four core factors shown. The EJC is recruited just upstream of exon-exon junctions after RNA splicing. UPF3B is a scaffolding factor that directly interacts with the EJC, UPF1, UPF2 and eukaryotic release factors (eRFs) 4, 24 .
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Analyses of the majority of the genes in a genome (for example, RNA sequencing analysis determines the level of RNAs transcribed from all significantly expressed genes in the genome).
In-frame
Codons that are in the same frame as the initiator codon.
Untranslated regions
(UTRs). The regions of an mRNA upstream and downstream of the coding region (that is, the 5 ′ UTR is upstream of the initiator codon and the 3 ′ UTR is downstream of the stop codon).
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UPF3B is a critical adaptor protein that physically links the EJC with the core NMD factors, thereby triggering RNA decay. Although an important NMD factor, UPF3B is not universally required for NMD; instead, evidence suggests that UPF3B directs a specific branch of the NMD pathway (fiG. 4a) . Thus, depletion of UPF3B from mammalian cell lines leads to upregulation of only some NMD substrates, providing evidence for UPF3B-dependent and UPF3B-independent branches of NMD 17, 37 . This model was confirmed by analysis of Upf3b-null mice, which upregulate some NMD substrates but not others 38 . Further evidence that UPF3B functions in only a branch of the NMD pathway is the finding that Upf3b-null mice progress through embryogenesis and reach adulthood 36 , whereas mice lacking factors crucial for the entire NMD pathway (for example, UPF1) suffer from early embryonic lethality 18, [39] [40] [41] [42] .
Together, these studies suggest that the UPF3B-dependent NMD branch is critical for normal behaviour. As we discuss later, one possible explanation is that RNAs specifically degraded by this branch of the NMD pathway have roles in developing and mature neural cells.
NMD genes and neural diseases. In addition to UPF3B, other genes in the NMD pathway have also been linked with ID and neural disease. For example, heterozygous deletions of the NMD gene UPF2 and adjacent genomic regions have been shown to be associated with ID and neurodevelopmental disorders 43 (TAble 1) . Further support for the involvement of UPF2 in psychiatric disorders comes from the identification of a de novo missense mutation in UPF2 in a patient with SCZ 44 . Further evidence that NMD defects cause neurological disease comes from a study by Nguyen et al. 43 , who found that copy number variations (CNVs) encompassing NMD genes were significantly associated with several types of neural dysfunction, including neurodevelopmental disorders (TAble 1) . Among genes exhibiting a significant copy number loss were UPF2 and UPF3A, the latter of which encodes an NMD repressor 42 , raising the possibility that not only too little NMD but also too much NMD can cause neural dysfunction. As further evidence for this 'Goldilocks' principle, copy number gain of several NMD genes was shown to be significantly associated with ID, neurodevelopmental disorders and brain malformations, including macrocephaly (TAble 1) . Together, these human genetic studies raise the possibility that either too much or too little of factors that are involved in NMD can cause neurological and psychiatric disorders.
Mutations in EJC genes are also associated with neurological disease (TAble 1) . For example, deletions in 1q21.1, a small region of human chromosome 1 that includes the gene encoding the EJC core component, RBM8A, is associated with increased incidence of ID, epilepsy, ASD and SCZ [45] [46] [47] . In support of a causal role, Rbm8a-haploinsufficient mice have dramatic neural defects, including microcephaly 48, 49 , a defect observed in many patients with 1q21.1 deletions 47 . As further evidence for a role of Rbm8a in neural function, overexpression of this EJC gene in mice increases anxiety-like behaviour, impairs social skills, decreases immobile time and enhances the frequency of miniature excitatory postsynaptic currents 50 . These data from EJC-deficient mice and humans raise the possibility that defects in NMD cause aberrant neuronal activation, neurodevelopmental disorders, microcephaly and epilepsy. However, it should be noted that EJC factors not only bind to splice junctions and function in NMD 51, 52 ; they also bind at other sites and function in several other molecular processes 22, 23 . Thus, disruption of one or more of these other processes is likely to have a major role in many of the phenotypic defects in EJC-deficient mice.
NMD and neural development
The finding that mutations in NMD factor genes are strongly associated with neural disease suggests that NMD is critical for neural development and/or function. However, the presence of a uORF or a long 3′ UTR does not necessarily trigger NMD; thus, these NMD-inducing features act only in specific contexts 110 .
In this section, we consider the former. We first go over the evidence for the role of the central NMD factor, UPF1, in neural stem versus neural differentiation decisions. We then discuss several studies conducted on the neural differentiation and maturation roles of the only NMD factor gene definitively shown to cause neural disease when mutated in humans: UPF3B [31] [32] [33] [34] [35] .
MicroRNA circuits controlling NMD. The first hint that NMD had a role in neural development was the discovery -by Bruno et al. 53 -that UPF1 is dramatically downregulated during mouse brain development. Later studies showed that this downregulation also occurs during both mouse and human neural cell differentiation in vitro [54] [55] [56] . Other NMD factors were downregulated as well, raising the possibility that NMD efficiency is decreased during neural differentiation, a possibility directly demonstrated using two independent NMD reporters 55 . Several lines of evidence indicated that this downregulated NMD response is critical for neural stem cells (NSCs) to differentiate 55 . Lou et al. found that preventing UPF1 downregulation during neural differentiation (through forced expression of modest levels of UFP1) inhibited neural differentiation. Conversely, the high levels of NMD factors inherent in stem cells were found to be sufficient to maintain 'stemness' , as depleting UPF1 triggered the differentiation of both mouse NSCs and neural precursor (P19) cells. Thus, the high expression level of NMD factors is essential to maintain neural precursor cells in a stem cell state.
NMD downregulation appears to be a general property of differentiation, as it has been shown to occur in several differentiation scenarios, including adipogenesis 57 , myogenesis 58 and endoderm differentiation 16 . In the case of the endoderm, the formation of this germ layer from human embryonic stem cells was found to critically depend on the NMD downregulatory response 16 . What is responsible for differentiation-dependent NMD downregulation? One class of factors that have a role in NMD downregulation is microRNAs (miRNAs) (fiG. 4b). A particularly critical NMD regulatory miRNA is the brain-enriched miRNA miR-128, which was found to repress NMD by targeting UPF1, UPF3B and the EJC core component MLN51 (also known as CASC3) 53, 55 . miR-128 is dramatically induced during neural differentiation and is at least partially responsible for the downregulation of NMD factors during neural differentiation on the basis of rescue experiments 53, 55 . An miRNA-based bistable feedback circuit was defined by Lou et al. that stabilizes the NSC state (when NMD is high) or promotes neural differentiation (when NMD is low) 55 . In addition to miR-128, other NMD-inhibitory miRNAs may participate in NMD downmodulation, including the brain-enriched miRNAs miR-9 and miR-124 (Ref. 55 ). Another recently defined NMD regulatory miRNA, miR-125 (Ref.
59
), has roles in the synaptic function of adult-born interneurons in the olfactory bulb 60 and neural stem differentiation 61 . How do NMD-factor dynamics influence whether a cell is in a stem cell state or differentiated? Lou et al. found that the majority of well-established pro-neural differentiation proteins are encoded by high-confidence NMD target mRNAs, supporting the possibility that NMD promotes the stem cell state by degrading pro-differentiation mRNAs 55 . Using a rescue experiment approach, Lou et al. identified the mRNA encoding one particular neural differentiation factor -SMAD7 -which must be degraded by NMD to maintain the NSC state 55 . These data supported a model in which Smad7 mRNA levels are low in NSCs because of high NMD magnitude, but upon receiving a neural induction signal, NMD efficiency is decreased, leading to stabilization of the Smad7 transcript and consequent neural differentiation. Lou et al. found that NMD also preferentially targets mRNAs encoding proliferation inhibitors, such as p21 and p27. The degradation of one or more of these mRNAs encoding proliferation inhibitors may explain how NMD promotes the proliferation of neural precursor cells 55 
.
Another likely mechanism by which NMD acts is by regulating the stability of alternatively spliced mRNAs. Alternatively spliced transcripts predicted to be targeted by NMD in the developing mouse and brain cortex are enriched for those encoding transcriptional regulators The normally spliced RNA is not targeted for decay by nonsense-mediated RNA decay (NMD) because its stop codon is not followed by an exon-exon junction, thus it avoids exon junction complex (EJC)-dependent NMD (fiGs. 1,2). By contrast, the four mRNAs depicted below the normally spliced mRNA have a context that triggers NMD, as they all acquire a premature translation termination codon (PTC) upstream of the final exon-exon junction as a result of alternative splicing. In the first three alternatively spliced transcripts shown, a PTC is created by a frameshift, which occurs by chance in two of three instances of alternative splicing. Intron retained RNAs are almost always degraded by NMD as they typically contain multiple stop codons in the retained intron (the occurrence of stop codons in random sequences is ~1:20). UPF, up-frameshift protein.
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and RNA-binding proteins 62 . Thus, the changes in NMD efficiency during neural differentiation could affect the stability and translation of these transcripts to influence brain development and function.
UPF3B affects neural differentiation. The studies described above demonstrate that a high magnitude of NMD promotes the NSC state and must be downregulated to initiate neural differentiation. However, Jolly et al. 54 obtained evidence that NMD has the opposite role at later stages of neural development -it promotes neural differentiation. In their study, Jolly et al. used mouse neural progenitor cells (generated from the mouse embryonic day 18.5 (E18.5) cortex) derived from older mouse embryos than the NSCs (derived from E14.5 brain) used by Lou et al. to show that NMD inhibits early stages of neural development 55 . Jolly et al. found that depletion of the NMD branch-specific factor UPF3B reduced the ability of mouse neural progenitor cells to differentiate 54 . This finding suggests that the UPF3B-regulated branch of NMD promotes the differentiation of already committed neural progenitor cells.
Further evidence that UPF3B promotes neuronal differentiation comes from a recent report from Huang et al. 36 , who found that NSCs from Upf3b-null mice exhibit hyper-self-renewal and poorly differentiate when cultured under conditions that efficiently differentiate control mouse NSCs. Together with the experiments of Lou et al., these results supported a model in which NMD must be downregulated to allow uncommitted stem cells and NSCs to begin neural differentiation, but that once committed to the neural cell lineage, NMD is crucial for these cells to proceed through neural differentiation and exit from the cell cycle.
An alternative (but not mutually exclusive) explanation for the results of Jolly et al. and Huang et al. is that the UPF3B-dependent branch of NMD has unique roles that differ from the NMD pathway as a whole. This explanation follows from the fact that Jolly et al. and Huang et al. manipulated the level of the branch-specific factor, UPF3B 54 , whereas Bruno et al. and Lou et al. manipulated the level of the central NMD factor, UPF1; thus, it is likely that the entire NMD pathway was modulated in the latter gain-and-loss-of-function experiments 53, 55 . Although the UPF3B-dependent branch of NMD may exhibit unique effects in neural cells, it is worth noting that in another system -human embryonic stem cells -UPF1 and UPF3B manipulation (whether depletion or forced expression) had very similar effects on primary germ layer differentiation 16 .
A specific function of UPF3B may be to control the formation of dendritic arborizations. Depletion of UPF3B in postmitotic hippocampal neurons caused a modest decrease in neurite length and an increase in arborization (branching) of both axons and dendrites of hippocampal neurons 54 . This finding suggests that UPF3B promotes neurite growth but suppresses neurite arborization. Unexpectedly, another study showed that overexpression of dominant-negative UPF3B mutant proteins (encoded by patients with ID with UPF3B mutations) led to dramatically decreased neurite arborization in a rat neural cell line 56 . It is not clear why these two different conditions that presumably both suppress NMD have opposite effects on neurite arborization 54, 56 . Regardless, the discovery that UPF3B affects neurites is potentially clinically significant, as both mouse models and post-mortem human studies have linked neuronal branching defects to several neurodevelopmental disorders 63 . A critical question for the future is to identify UPF3B target transcripts as a first step towards understanding how UPF3B influences neuronal differentiation and maturation. Towards this end, UPF3B-regulated transcripts have been identified in human lymphoblastoid cells 64 , and more recently UPF3B-regulated transcripts were defined in the frontal cortex 36 . Among the candidate UPF3B target transcripts identified in the frontal cortex (those upregulated in Upf3b-null mice and harbouring NMD-inducing features) were several known to have roles in neural development, function and disease, including AKR1C14, BRCA2, CDH24, DSCAM, FBN2, KCNH4, PTCH1 and RMST.
Another important future goal is to make use of model organisms in addition to mice to define conserved functions of NMD in neural development. In this regard, morpholino-mediated knockdown of NMD factors in zebrafish embryos has been shown to cause brain patterning and growth defects 65 . These NMD-deficient zebrafish embryos exhibited extensive CNS necrosis, aberrant eye development and brain patterning defects, particularly at the midbrain-hindbrain boundary. The same set of defects was elicited by knockdown of any of several different NMD factors (UPF1, UPF2, SMG5 or SMG6), suggesting that deficient NMD was responsible.
EJC mouse mutants exhibit robust neurodevelopmental defects. As described above, the EJC is recruited to splice junctions after RNA splicing, where it functions as a branch-specific NMD factor or NMD amplifier. Importantly, the EJC has other functions, including influencing RNA splicing, nuclear-cytoplasmic RNA transport efficiency, translation and cytoplasmic [31] [32] [33] [34] [35] Pedigree analysis of UPF3B mutations indicates causality in intellectual disability (ID). The evidence for other nonsense-mediated decay (NMD) genes being involved in neural disease is less strong. Only statistically significant associations of copy number variations (CNVs) with neural disease are shown, but note that the CNVs often amplify or delete other genes in addition to the NMD and exon junction complex genes indicated. ADHD, attention-deficit hyperactivity disorder ; ASD, autism spectrum disorder ; RCP, rhizomelic chondrodysplasia punctate; SCZ, schizophrenia; TAR , thrombocytopenia with absent radius; UTR , untranslated region.
NatuRe Reviews | NEuRosCiENCE RNA localization 22, 23 . Given this, EJC component-deficient mice would be predicted to exhibit more severe phenotypes than NMD factor-deficient mice. Consistent with this prediction, even a modest reduction in EJC factor levels (as a result of haploinsufficiency) causes severe phenotypic defects. For example, mice with loss of one allele of the EJC factor gene Magoh suffer from microcephaly and several brain cortical defects, including decreased thickness of all cortical layers, few intermediate neural progenitors, premature generation of neurons and extensive apoptosis 66 . Aberrant mitosis was found to be a likely culprit for at least some of these defects 67 . Deletion of one allele of two other core EJC factor genes -Rbm8a and Eif4a3 -in neural progenitors causes essentially the same defects as observed in Magoh heterozygotes 48, 49 , consistent with the idea that these phenotypes reflect impairment of EJC function in neural development.
Several indirect lines of evidence suggest that some of the neural defects caused by EJC factor haploinsufficiency result from perturbed NMD. First, NMD has been shown to be deficient in EJC factor-haploinsufficient neural progenitors 49 . Second, depletion of the EJC factor RBM8A promotes the proliferation and inhibits the differentiation of neural cells in vitro, a phenotype also exhibited by UPF1-deficient neural cells 55, 68 . Finally, the defining feature of EJC factor insufficiency -microcephaly -is also observed in a subset of patients with ID with mutations in the NMD factor gene UPF3B 31, 34 . Although this constitutes some evidence that NMD deficiency has a role in the severe defects in EJC heterozygotes, it is important to note that few or no defects have been observed in mice heterozygous for NMD factor genes [39] [40] [41] , raising the possibility that EJC factors are more important for non-NMD functions than NMD functions.
An alternative explanation for the more severe phenotype of EJC mutants than of NMD factor mutants is that EJC factors are more limiting for NMD than NMD factors in neural cells. To tease out the independent contributions of the EJC's various functions to specific phenotypes, it will be critical to identify EJC factor mutants with selective functional defects. This approach has been used to define the function of the NMD protein SMG6 in mouse embryonic stem cell differentiation. Thus, mutants of SMG6 that selectively perturb either its NMD or telomerase-promoting functions have allowed investigators to assign its NMD function as being responsible for its ability to drive mouse embryonic stem cell differentiation 18 .
NMD and neuronal function
In addition to its roles in developing neurons, NMD has functions in fully differentiated neurons. In this section, we review the evidence for NMD's roles in axon guidance and synaptic plasticity.
NMD in axon guidance. Axon guidance is the process by which axons are guided and ultimately form connections with their synaptic targets. One of the best known axonal guidance mechanisms involves the SLIT proteins, which are secreted extracellular matrix proteins that are recognized by the cell-surface roundabout (ROBO) proteins located on the tips of elongating axons [69] [70] [71] [72] . Two of the ROBO proteins -ROBO3.1 and ROBO3.2 -are generated by alternative RNA splicing from a single gene. ROBO3.2 is a shortened form of ROBO3 with a novel carboxyl terminus (fiG. 5) . The roles of ROBO3.1 and ROBO3.2 in axon guidance have been well studied in commissural axons, which cross midline structures in the brain. ROBO3.1 and ROBO3.2 protein exhibit highly specific spatial and temporal expression within commissural axons (fiG. 5 ) and the precise timing and location of these two proteins are known to be critical for the proper guidance of commissural axons in the spinal cord In order for NMD to modulate the levels of its target RNAs, it must be regulated. Several NMD regulatory factors, including those shown here, have been identified. One target RNA critical for the ability of NMD to dictate neural stem cell versus differentiation decisions is Smad7 mRNA , which encodes a negative regulator of TGFβ signalling and promotes neuronal differentiation
55
. Many candidate RNAs that might function downstream of NMD in its other neuronal roles have been identified, including Robo3.2 mRNA , which encodes a protein involved in axon guidance 73 . EJC, exon junction complex; UPF, up-frameshift protein.
Haploinsufficiency loss of one copy of a gene from a diploid organism.
Commissural axons
Neurites (projections from the cell body) that cross the midline of the CNs to the other side of the nervous system.
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protein enhances the ability of ROBO1 and ROBO2 to sense SLIT, and, as a result, the axon becomes repelled from the SLIT-expressing midline 69 . Thus, the selective induction of ROBO3.2 after axons have crossed the midline ensures that the axon loses its initial attraction to the midline so that the axon can elongate away from the midline.
Robo3.2 mRNA differs from Robo3.1 mRNA only in possessing a retained intron. This retained intron shifts the reading frame of the main ORF, leading to the introduction of a stop codon upstream of exon-exon junctions and hence the potential to be degraded by NMD. Indeed, Colak et al. 73 , a subset of neurons for which the axons cross midline structures in the brain. In the case of spinal commissural neurons, the axons express roundabout 3.2 (Robo3.2), an alternatively spliced transcript encoded by the Robo3 gene. The ROBO3.2 protein enhances the activity of other ROBO proteins, such as ROBO1 and ROBO2, which detect and mediate the chemorepellent effect of axons towards SLIT proteins found in the midline. When axons are undergoing migration to the midline (pre-crossing, top image), Robo3.2 mRNA accumulates in RNA granules in a non-translated state. When the axon encounters the midline (middle image), midline-derived factors trigger the translation of Robo3.2 mRNA , presumably , in part, by triggering their release from granules. Translation of Robo3.2 mRNA also triggers its decay by NMD (post-crossing, bottom image), thereby allowing only a short burst of ROBO3.2 protein production to enhance the function of ROBO1 and ROBO2 and enable the axon to be repelled by SLIT in the midline.
instead Robo3.2 mRNA is degraded after a lag period in post-pioneer rounds of translation.
How can NMD occur after the pioneer round of translation? In a widely recognized model, NMD is triggered when NMD factors that are normally recruited to the eRF-bound ribosome upon translation termination interact with EJCs 27, 75 . However, this interaction would not occur if the ribosome is disassembled and released from the stop codon before it interacts with the EJC. Therefore, highly efficient ribosome disassembly at stop codons would prevent the stop-codon-bound ribosome from detecting a downstream EJC. Alternatively, if the interaction with the EJC forms slowly, then ribosome release will occur before NMD is induced. Thus, a slow rate of ribosome disassembly would facilitate NMD occurring in the first round, whereas rapid ribosome disassembly may require multiple rounds of translation before the stop-codon-stalled ribosome can interact with the EJC. The rate of ribosome disassembly could be regulated, for example, by the level of ribosome-release factors 76 . Regardless of the underlying mechanism, it is clear that mRNAs can -under certain circumstances -be recognized by NMD after the pioneer round of translation 77, 78 . On the basis of this model, NMD is intrinsically inefficient in commissural neuron axons; thus, several rounds of ROBO3.2 protein synthesis typically occur before Robo3.2 mRNA is degraded via the NMD pathway. Perhaps NMD is downregulated specifically in commissural neuron axons to allow for this outcome, a possibility supported by the evidence that NMD magnitude is highly regulated in developing neurons 53, 55, 56 . It is intriguing to also speculate that different types of neuron may have different NMD efficiencies; indeed, even individual axons may differ in NMD efficiency. As a result, specific axons would produce different amounts of ROBO3.2 and other proteins from NMD target mRNAs, which could be used as a strategy in commissural neuron axons to determine the precise degree of repulsion of the commissural axons from the spinal midline, thereby leading to targeting to different positions in the spinal cord.
The ability of translational activation coupled with NMD to both generate protein and trigger RNA decay is seemingly contradictory. We suggest that this 'drive with both the gas and brake' strategy allows for a transient bolus of protein to be made in a highly regulated manner. In the case of ROBO3.2, it allows for transient production of this protein specifically when the axon reaches the midline, thus restricting its axonal repulsive action to precisely when it is needed. We also suggest that this coupled translation induction-RNA decay system is a general strategy that could be used in other settings. For example, coupled translation-RNA decay could provide a means to trigger the transient production of specific proteins in mature neurons to confer synaptic plasticity and thereby store memories. It will be important to identify RNAs in addition to Robo3.2 that undergo coupled translation and RNA decay in neurons. It will also be interesting to determine whether UPF3B contributes to the degradation of Robo3.2 because it could link this form of regulation to neurodevelopmental phenotypes seen in humans with UPF3B mutations 31 .
Local translation may serve as a trigger for NMD in neurites. A prime target for this type of local regulation is mRNAs that are not allowed to be translated when they first reach the cytoplasm from the nucleus. Such mRNAs become translationally active only after they are transported to dendrites or axons 79 . Because NMD requires translation 80 , such RNAs would not be predicted to be degraded by NMD until they reached these distal sites. Support that this type of regulation may occur commonly is the finding that EJC proteins, such as EIF4A3, are abundant in RNA transport granules in dendrites 81 . Accumulation of EJC proteins would be expected if many mRNAs in such granules have not yet undergone translation and thus retain EJC proteins bound at exon-exon junctions.
Local NMD control may also be exerted in other ways and at other sites within neurons. A hint that this is the case is the finding that NMD factors are enriched in neurites 56, 73, 81 . Perhaps this allows NMD to be spatially localized, enabling mRNA degradation to occur at specific sites in neurons, such as distal axons.
NMD efficiency may also be regulated during development. In support, the NMD factor UPF3B exhibits a different nuclear-to-cytoplasmic distribution in developing neurons that depends on the stage of development. Neural progenitor cells within the ventricular zone from E10.5 and E14.5 mice express predominantly cytoplasmic UPF3B, whereas neural progenitor cells at a later stage (E18.5) express mainly nuclear UPF3B 54 . Thus, NMD efficiency may be reduced at later stages in development owing to lack of availability of UPF3B in the cytoplasm. It will be interesting to elucidate the molecular underpinnings behind this cytoplasmic-to-nuclear switch and to determine whether the efficiency of NMD is indeed reduced as a result of UPF3B relocalization.
NMD in synaptic plasticity. NMD has also been implicated as having a role in synaptic plasticity, the process in which synaptic strength is altered in response to shifts in synaptic activity. There is considerable interest in this process, as synaptic plasticity is thought to underlie learning and memory. The first hint that NMD might have a role in synaptic plasticity was the discovery that NMD degrades the mRNA encoding ARC 81 , a cytoskeletal-associated protein enriched in dendrites that accumulates at synapses upon neural stimulation and functions in synaptic plasticity 82, 83 . The Arc gene is unusual in that it responds to neural stimuli by undergoing not only rapid transcriptional activation 84 but also rapid decay of its mRNA.
Several lines of evidence suggest that Arc mRNA instability is driven by NMD. First, Arc mRNA has two introns in its 3ʹ UTR and thus has two EJC landing pads downstream of its stop codon, which would be predicted to trigger NMD (fiGs. 1,2). The ability of these two introns to trigger NMD was recently directly shown in reporter experiments 85 . Second, Arc mRNA is bound by EIF4A3 (Ref.
81 ). Finally, knockdown of either UPF1 or the EJC factor, EIF4A3, triggers Arc mRNA upregulation 81 . As described below, the find that Arc mRNA is an NMD target has important implications for how it is regulated and how it functions in synaptic plasticity.
How does NMD influence the spatial and temporal pattern of Arc expression after synaptic stimulation? Arc mRNA instability by NMD allows ARC to achieve its highly transient induction in response in neuronal stimulation 86 . This observation follows from the known relationship of RNA synthesis and decay kinetics: transcriptionally induced unstable mRNAs reach steady state more quickly than do stable mRNAs, and unstable mRNAs decline more rapidly than do stable mRNAs after transcriptional shut-off 87 . Thus, the instability of the Arc mRNA, coupled with its rapid transcriptional induction, allows the ARC protein to be strongly and transiently expressed in activated neurons. Of note, it was recently shown that ARC translation is stimulated by brain-derived neurotrophic factor through an RNA splicing-dependent and 3′ UTR-dependent mechanism 85 . This observation provides another level of regulation (also acting through the 3′ UTR) that drives the unique expression pattern of ARC in neurons.
With regard to Arc's spatial regulation, this has been studied in depth by Farris et al. 84 . In their model system, a single electroconvulsive seizure in rats triggers rapid Arc mRNA induction in the dendrites of neurons in the dentate gyrus. Subsequent in vivo synaptic activation drives Arc mRNA to become specifically localized at the synapse and largely disappear from synaptically inactive dendritic domains. Farris et al. obtained several lines evidence that this pattern of expression is achieved by two events: delivery of newly synthesized Arc mRNA to activated dendritic domains (for example, near synapses) and Arc mRNA degradation throughout dendrites 84 . The net result of this twofold mechanism is selective accumulation of both Arc mRNA and locally translated ARC protein at activated synapses.
NMD is likely to be responsible for the dendritic decay of Arc mRNA for three reasons. First, Arc mRNA is a well-established NMD substrate, as described above. Second, both UPF1 and EJC components are present all along dendritic processes 81 . Third, Farris et al. found that local introduction of the translation inhibitor cycloheximide (CHX) into the dentate gyrus region greatly increased Arc mRNA levels in dendrites 84 . Given that NMD absolutely depends on translation 80 , this provided evidence that Arc mRNA degradation in dendrites depends on NMD. As evidence for specificity, another mRNA localized to synaptic regions of dendrites -Camk2a mRNA -is not subject to translation-dependent mRNA downregulation in response to synaptic activation 84 . Interestingly, Farris et al. found there was one dendritic site that did not exhibit a significant increase in Arc expression in response to CHX -the outer dendritic region. Might this region lack NMD? Perhaps there is little or no translation in this outer dendritic region. Alternatively, this site may have active NMD, but Arc mRNA is specifically immune to its effects in this region. Regardless of the underlying mechanism, the ability of local NMD to regulate the levels of its target transcripts in a temporally and spatially restricted manner in specific dendritic regions has potential implications for synaptic plasticity and other neuronal functions.
Arc mRNA also appears to be regulated by NMD in a stimulus-specific manner. Farris et al. found that electroconvulsive-seizure-induced Arc mRNA -which is broadly expressed across dendrites -is only modestly subject to translation-dependent downregulation 84 . By contrast, subsequent in vivo synaptic stimulation leads to strong translation-dependent downregulation of Arc mRNA in a dendritic region-specific manner, as described above. Together, these results support a model in which synaptic activation triggers a dramatic increase in Arc mRNA decay in a region-specific manner through the NMD pathway. It will be interesting to determine whether this reflects an Arc-specific regulation by NMD or a generalized shift in NMD magnitude. In support of synaptic stimulation regulating NMD magnitude, the NMD factor gene UPF3B has been shown to exhibit reduced expression in hippocampal neurons undergoing chronic depolarization 54 . To more directly examine how NMD influences synaptic activity, Giorgi et al. 81 evaluated the role of the NMD-promoting factor EIF4A3 in neurons. As described above, EIF4A3 is poised to play a role in synaptic functions as this EJC factor is concentrated in neurites, where it is present in ribonucleoprotein complexes bound to NMD target mRNAs. EIF4A3 also associates with dendritic proteins such as be FMRP (encoded by the FMR1 gene) 81 . Giorgi et al. found that EIF4A3 knockdown significantly increased excitatory miniature postsynaptic currents mediated by AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors in cortical neurons. In addition, AMPA receptor level was increased at putative synaptic sites. Together, these data suggest that EIF4A3 normally acts as a brake on synaptic strength.
Although the studies described above focused on Arc, many other high-confidence NMD substrates have been identified in the brain 36, 62, 81 , and potential NMD targets transcripts (for example, those with retained introns) are localized in dendrites 88, 89 . Thus, Arc is only one of many transcripts likely to be regulated by NMD in axons and dendrites. We suggest that NMD degrades diverse mRNAs at synapses to enable transient expression of their encoded proteins and thereby avoid overly prolonged synaptic translational activation. By shaping both the temporal and spatial expression pattern of the synaptically induced ARC and other proteins, NMD may be critical for 'synaptic consolidation' , thereby explaining why defects in NMD cause ID in humans and mice 31, 36 . In this regard, it is interesting to note that rats introduced to a novel learning environment downregulate Arc mRNA in a translation-dependent manner 84 , raising the possibility that NMD is critical for this form of learning.
Further evidence for a role of NMD in synaptic function comes from flies. Mutations in the NMD gene Smg1 cause photoreceptor synaptic transmission defects, impaired synaptic structural architecture, decreased terminal arborization size, branching and presynaptic terminal defects at neuromuscular junction synapses in Drosophila melanogaster 90 . In support of the notion that NMD is responsible for these functions, Long et al. found that mutations in two other NMD genes -Upf2 and Smg6 -caused similar impairments 90 . Together with the data described above from mammalian synapses, it appears that NMD serves as an evolutionarily conserved mechanism to influence synaptic events.
NMD drives a neural expression programme. NMD can be used to ensure that a gene exhibits a temporally regulated and cell-type-specific pattern of gene expression. This was recently described for the gene encoding PSD95 (also known as DLG4), a scaffold protein essential for synaptic maturation and plasticity that is highly expressed in mature neurons. Zheng et al. 91 showed that whereas the Psd95 gene is transcribed broadly, the PSD95 protein is selectively expressed in neurons through a post-transcriptional mechanism involving NMD. In early embryonic neural development and in non-neuronal cell types, the polypyrimidine tract-binding proteins, PTBP1 and PTBP2, repress the splicing of PSD95 exon 18, leading to the generation of a PTC and decay by the NMD pathway 92 . PTBP1 and PTBP2 are downregulated later in brain development, allowing for exon 18 inclusion, consequent escape from NMD and high level expression of PSD95. Thus, this study provides evidence that alternative splicing coupled with NMD -commonly referred to as ' AS-NMD' -is one means to establish neuron-specific gene expression. An important question for the future is whether the decay of the exon 18-skipped PSD95 mRNA by NMD is crucial for normal neural development. For example, this mRNA may be degraded by NMD because it encodes a dominant-negative protein that interferes with synaptic maturation.
NMD as a therapeutic target in disease
In this section, we advance the notion that 'NMD therapy' may ameliorate the symptoms of patients with some neural diseases.
NMD and amyotrophic lateral sclerosis. The notion that neurodegenerative diseases are a potential clinical target for NMD therapy was first suggested by studies on an inherited form of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig disease. Two groups developed yeast ALS models expressing the human FUS gene (also known as TLS), encoding fused in sarcoma (FUS). This experiment resulted in cytotoxicity and cytoplasmic inclusion bodies, thereby replicating what is observed in the cells of patients with ALS 93, 94 . To screen for genes that suppress this toxicity, these groups introduced plasmids overexpressing most known yeast genes. These screens identified a small group of yeast genes, most of which encode RNA-metabolism proteins and RNA-binding proteins.
One of the yeast genes that suppressed the toxicity of the mutant FUS was the gene encoding ECM32, an RNA helicase related to human UPF1. This finding led one of the groups to test human UPF1, which they found also suppressed FUS-mediated toxicity in their yeast ALS model 93 . Two lines of evidence suggested that human UPF1 rescues FUS-mediated toxicity through the NMD pathway. First, overexpressed human UPF1 appeared to stimulate NMD on the basis of downregulated expression of one endogenous NMD substrate RNA. Second, overexpression of two other NMD factors -human UPF2 and UPF3B -also rescued yeast cells from the toxic effects of FUS.
To assess whether these findings in yeast apply to mammals, Jackson et al. 95 used a rat model of TAR DNA-binding protein 43 (TDP43; also known as TARDBP)-induced motor paralysis. In this model, TDP43 is expressed in rat spinal cord, resulting in limb paralysis similar to that seen in human ALS. To simulate a therapeutic approach that might be used in humans, the authors overexpressed human UPF1 from an adeno-associated virus (AAV) vector and observed that this UPF1-AAV therapy improved motor function, motor coordination, grip strength and forelimb function in their ALS rat model. Similar results were seen by Barmada et al. 96 , who tested whether enhanced NMD could protect from either TDP43 and FUS/TLS-mediated neurotoxicity in rodent neurons. They found that the decreased survival of primary rodent cortical neurons triggered by either FUS or TDP43 (wild type or mutant) was rescued by expression of human UPF1. Of note, the protective effect of UPF proteins was specific for FUS-induced and TDP-induced ALS, as it was not observed in other models of neurotoxicity, such as a Huntington disease model and ALS disease triggered by mutant superoxide dismutase.
How does overexpressed UPF1 protect from FUS-induced and TDP-induced toxicity? Barmada et al. obtained several lines of evidence that overexpressed UPF1 acts by elevating the magnitude of NMD 96 . First, the chemical NMD inhibitor 1 (NMDI) reversed the protective effect of UPF1. Second, another NMD factor, UPF2, also rescued toxicity. Third, even greater protection was seen upon forced co-expression of both UPF1 and UPF2 (Ref.
96
). Finally, expression of an RNA helicase that has been shown to function in NMD, MOV10, also rescued toxicity 97 . It is commonly assumed that the accumulation of cytoplasmic FUS-containing and TDP43-containing bodies in neuronal cells from patients with ALS is responsible for ALS symptoms. Inconsistent with this assumption, UPF1 and UPF2 overexpression greatly reduced the toxicity of FUS and TDP43 overexpression without reducing the formation of the cytosolic inclusion bodies in yeast 93 . This finding raises the possibility that the inclusion bodies present in cells of patients with ALS are not responsible for toxicity.
Why might overexpressed UPF1 and UPF2 suppress ALS-induced toxicity? One possibility is that these NMD factors are rate limiting in neural cells; thus, their overexpression increases NMD magnitude as a means to combat an increased need for NMD in ALS. This observation follows from the fact that FUS and TDP43 are RNA splicing factors; thus, when their function is impaired in ALS, this would be expected to lead to high levels of mis-spliced mRNAs, many of which are NMD substrates. In support of this model, mutant FUS and TDP43 are largely lost from the nucleus of neuronal cells from patients with ALS and instead accumulate in cytoplasmic granules 98 . Because RNA splicing occurs in the nucleus, mislocalization to the cytosol would www.nature.com/nrn be predicted to disrupt the nuclear functions of these RNA splicing factors, thereby leading to the accumulation of mis-spliced RNAs. The massive increase in such mis-spliced RNAs could overload the NMD machinery, thereby creating a need for more NMD factors (fiG. 6) .
In support of the idea that there is an increase in the load of mis-spliced RNA, studies have detected elevated levels of retained introns in transcripts in the spinal cord of mice expressing an ALS-associated FUS mutation 99 . It is well established that retained introns are NMD substrates, as most introns contain stop codons in all three reading frames and thus have PTCs, a key feature that triggers NMD.
How does an accumulation of mis-spliced mRNAs lead to ALS toxicity? If such mRNAs are not efficiently degraded by NMD, their translation would be expected to produce truncated proteins, some of which probably act as dominant-negative proteins. These proteins may themselves be toxic, or they may activate neuronal stress responses normally triggered by misfolded proteins.
Together, these studies suggest a model in which ALS and NMD are intimately intertwined, providing a potential rationale for therapeutic augmentation of NMD in the treatment of this disease. Insufficient levels of NMD may also be involved in other diseases that have been linked to sequestration of RNA splicing factors, such as trinucleotide repeat-expansion diseases 100 . Similarly, spinal muscular atrophy is associated with impaired RNA splicing owing to inefficient assembly of spliceosome subunits 101 . As described below, we suggest that restoring normal NMD activity through NMD therapy could potentially restore normal function.
NMD activation therapy. In order to reverse NMD deficiency in neurodegenerative diseases such as ALS, it is critical to devise therapeutic approaches to elevate the magnitude of NMD. How can this be achieved? One approach is to overexpress NMD factors such as UPF1 or UPF2 with viral vectors as done by Jackson et al. and Barmada et al. 95, 96 . However, the efficiency of delivery, particularly in the brain, will likely be challenging. Another approach is to develop small-molecule NMD activators. Although many small-molecule NMD inhibitors have been identified and applied to clinical scenarios 6, 102, 103 , no well-defined NMD activators have been discovered. One appealing strategy is to screen for inhibitors of UPF3A, which was recently shown to be an NMD repressor 42 , and thus UPF3A inhibitors would be predicted to activate NMD. Another strategy is to identify activators of SMG1, the kinase that phosphorylates UPF1 and is essential for NMD 27, 104, 105 . Although NMD activators could be beneficial for neurodegenerative diseases associated with impaired function of RNA splicing factors or NMD proteins, it is possible that these activators could also have unwanted side effects. For example, NMD activators would be Up-frameshift protein 1 (UPF1) and UPF2 overexpression reverses the neurotoxic effects of mutant fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP43) in amyotrophic lateral sclerosis (ALS) disease models 95, 96 . This raises the possibility that these neurodegenerative diseases are caused by insufficient NMD, which is restored by UPF1 or UPF2 overexpression. In normal cells (top), properly spliced mRNAs predominate, as NMD degrades most aberrantly spliced mRNAs. By contrast, ALS diseased cells (middle) often make mutant versions of TDP43 or FUS protein that are mislocalized to the cytoplasm, which prevents their ability to regulate RNA splicing and thus leads to widespread aberrant splicing 99 . NMD may not be sufficient to fully degrade this increased load of aberrantly spliced transcripts, leading to increased translation of abnormal proteins that cause neurotoxicity. The protective effects of UPF1 and/or UPF2 overexpression may extend to other diseases associated with impaired RNA splicing. In the case of myotonic dystrophy (bottom), the splicing factor, muscleblind-like splicing regulator 1 (MBNL1), is sequestered in nuclear RNA granules, resulting in impaired MBNL1-dependent RNA splicing 100 .
Although not yet experimentally tested, this leads to the hypothesis that the toxicity of these mis-spliced mRNAs may also be mitigated by UPF1 and UPF2 overexpression. FTD, frontotemporal dementia.
predicted to destabilize critical NMD target RNAs, such as Arc, which could impair synaptic plasticity and learning.
NMD inhibition therapy.
There has been considerable interest in identifying agents that inhibit the NMD pathway, as they would be expected to elevate the expression of mutant PTC-bearing genes that still encode a functional protein. For example, some types of muscular dystrophy are caused by point mutations that do not abolish protein function but cause the Dmd mRNA to be degraded by NMD 106, 107 . By inhibiting NMD, levels of mutant -but still functional -Dmd mRNA could be elevated, thereby potentially reducing disease symptoms. Likewise, NMD inhibitors have the potential to treat neural diseases caused by nonsense or frameshift mutations that do not completely ablate function. Several NMD inhibitors have already been identified, many with defined biochemical functions 102, 103, 108, 109 ; thus, the field is poised to investigate the clinical utility of such agents. Given that NMD inhibitors would be predicted to enhance ARC expression, another interesting potential future application is to determine whether such agents enhance synaptic plasticity after synaptic activation and thus improve learning and memory in neurodegenerative and neurodevelopmental diseases associated with impaired synaptic function.
Concluding remarks
NMD is emerging as a critical regulator of neuronal development and function and more recently as a potential regulator of neuronal viability in disease contexts. Insufficient NMD may underlie neurodegenerative diseases, such as ALS, which are caused by sequestration of RNA splicing factors. NMD suppression may be valuable for enhancing the expression of synaptic proteins and synaptic function. It will be important for future studies to direct their efforts towards designing NMD modulators to treat neurodegenerative disease and other neural disorders.
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Frameshift insertions and deletions downstream of the initiator codon that are not a multiple of three and thus shift the reading frame (this leads to altered amino acids in the encoded protein downstream of the frameshift).
